SWTX's desmoid tumor drug, Ogsiveo, is driving its top line. The recent FDA nod for Gomekli to treat a rare tumor diversifies its commercial portfolio.
SpringWorks Therapeutics is working on new potential indications for its IP portfolio while running additional trials. See ...
Over the last 7 days, the United States market has dropped by 4.4%, yet it has risen by 7.5% over the past year, with earnings forecasted to grow by 14% annually. In this environment, identifying high ...
Ogsiveo's net product revenues were $172 million in 2024. Last month, the FDA approved SpringWorks’ MEK inhibitor, Gomekli (mirdametinib) for the treatment of adult and pediatric patients 2 ...
In a report released today, Alec Stranahan from Bank of America Securities reiterated a Buy rating on Candel Therapeutics (CADL – Research ...
Bank of America Securities analyst Alec Stranahan reiterated a Buy rating on Meiragtx Holdings (MGTX – Research Report) today and set a price ...
4d
Stocktwits on MSNSpringWorks Therapeutics Leads Biotech Pack In Weekly Retail Follower Surge: What's Fueling Interest?SpringWorks Therapeutics (SWTX) saw the biggest retail follower increase among biotech stocks last week on Stocktwits, even ...
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Get Free Report) saw some unusual options trading on Thursday. Traders acquired 13,068 call options on the stock. This is an increase of 223% compared to ...
Hard on the heels of the disclosure that Merck KGaA is talking to SpringWorks about a possible takeover, a new FDA approval could have sweetened the deal. Stamford, Connecticut-based SpringWorks ...
The U.S. Department of Agriculture announced Wednesday that its Local Food for Schools (LFS) program is ending. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results